Emergent BioSolutions Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 2, 2022 and accepted by EDGAR at Aug 1, 2022, 18:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $242.7m | us-gaap:Revenues |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $550.2m | us-gaap:Revenues |
| Gross profit | 3 months2022-04-01 to 2022-06-30 | $65.6m | us-gaap:GrossProfit |
| Gross profit | 6 months2022-01-01 to 2022-06-30 | $207.6m | us-gaap:GrossProfit |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $49.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $96.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $81.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $165.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$72.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$65.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $7.8m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $16.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-04-01 to 2022-06-30 | −$26.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | −$26.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$56.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$60.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$1.13 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$1.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$1.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$1.19 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 50,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 50,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$52.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $64.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2022-01-01 to 2022-06-30 | $81.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-06-30 | $358.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $1.08bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $2.74bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $276.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $1.22bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $793.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-06-30 | $31.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-06-30 | $1.51bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001367644-22-000119. Last ingested by Listed: Nov 4, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.